CAR治疗技术用于恶性血液肿瘤：B细胞急性淋巴细胞白血病...

icartab

CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Chimeric antigen receptor (CAR) T-cell therapy has recently come into the spotlight due to impressive results in patients with B-cell acute lymphoblastic leukemia. By targeting CD19, a marker expressed most B-cell tumors, as well as normal B cells, CAR T-cell therapy has been investigated as a treatment strategy for B-cell leukemia and lymphoma. This review will discuss the successes of this therapy for the treatment of B-cell acute lymphoblastic leukemia and the challenges to this therapeutic strategy. We will also discuss application of CAR T-cell therapy to chronic lymphocytic leukemia and other B-cell malignancies including a follicular lymphoma, diffuse large B-cell lymphoma, as well as acute and plasma cell malignancies.
KEYWORDS:
B-cell malignancies; CAR; T cells; autologous T-cell infusion; chimeric antigen receptor; immunotherapy
CAR治疗技术用于恶性血液肿瘤：B细胞急性淋巴细胞白血病的成功治疗能否用于其他血液系统恶性肿瘤的治疗？

CAT-T细胞治疗技术最近备受瞩目，由于它对于B细胞急性淋巴细胞白血病的病人具有令人印象深刻的治疗效果。通过靶向CD19，一个在B细胞肿瘤表面高度表达的标志物，CAR-T细胞治疗已经被开发作为一种治疗B细胞白血病和淋巴瘤的治疗策略。这篇综述将讨论使用这个技术治疗B细胞急性淋巴细胞白血病取得的成功以及这种技术面临的挑战。我们也将讨论到CAR-T技术在慢性淋巴细胞白血病和其他B细胞恶性肿瘤，包括滤泡性淋巴瘤，弥漫性大B细胞淋巴瘤，以及急性和血浆细胞恶性肿瘤中的应用。

关键词：
细胞恶性肿瘤；CAR；细胞；自体T细胞输注；嵌合抗原受体；免疫疗法
出自爱康得生物技术